((自动化翻译由路透提供，请见免责声明 ))
10月31日 - ** Harmony Biosciences 二次发行定价后，股价盘前下跌5.3%，至32美元。 ** 以罕见神经疾病为重点的制药公司周三晚些时候宣布， (link) 800万股，由Marshman Fund Trust和Valor Equity Partners以31美元的价格出售。
** HRMY 股价周三暴跌 18.5%，收于 33.80 美元，创去年 10 月以来最大单日跌幅。 ** 根据美国证券交易委员会的招股说明书文件，Marshman 减持了 400 万股，使其持有的(股份达到约 670 万股，占) 股份的 11.7%，而总部位于芝加哥的 PE 公司 Valor 的 (link) 持股达到约 720 万股，(占) 股份的 12.7%。 (link) ** 周二，HRMY 股价上涨 16.1%，报收于 41.49 美元，该公司公布的 (link) 第三季度营收和 GAAP 每股收益均高于共识水平。
** 截至本周三，股价累计上涨约 5%。2023 年 10 月 31 日股价收于 23.54 美元
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.